Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial

Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35

(2021) N. Lynn Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Medication Use for the Risk Reduction of Primary Breast Cancer in Women

(2019) Heidi D. Nelson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

On longitudinal prediction with time-to-event outcome: Comparison of modeling options

(2016) Marlena Maziarz et al.   BIOMETRICS

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

(2016) Patricia A Ganz et al.   LANCET

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

(2016) Richard G Margolese et al.   LANCET

The use of repeated blood pressure measures for cardiovascular risk prediction: a comparison of statistical models in the ARIC study

(2016) Michael J. Sweeting et al.   STATISTICS IN MEDICINE

Fallacies of last observation carried forward analyses

(2015) John M Lachin   Clinical Trials

Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time-Dependent Covariates

(2007) R. Schoop et al.   BIOMETRICS